RALEIGH, N.C.--(BUSINESS WIRE)--Aug. 28, 2006--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the U.S. Food and Drug Administration has granted COLAZAL(R) additional marketing exclusivity through January 8, 2007. The exclusivity is based upon the FDA’s acceptance of the clinical package the Company submitted on June 20, 2006 in response to a Written Request received from the U.S. Food and Drug Administration for clinical information about the safe and effective use of COLAZAL in pediatric patients between 5 and 17 years of age with ulcerative colitis. The FDA has informed Salix that the new marketing exclusivity expiration date for COLAZAL will be posted in the Electronic Orange Book (EOB) at the EOB’s next update. Historically, the EOB has been updated on a monthly basis.
